Inspire Medical Systems (INSP) risk factors, FY2024 10-K

Risks Related to Our Business

1. 01We have historically incurred significant operating losses, we may incur operating losses in the future, and we may not be able to sustain profitability
2. 02Our revenue is primarily generated from sales of our Inspire system and we are, therefore, highly dependent on it for our success
3. 03If patients or physicians are not willing to change current practices to adopt our Inspire therapy to treat moderate to severe OSA, our Inspire therapy may fail to gain increased market acceptance, and our business will be adversely affected
4. 04If we are unable to achieve and maintain adequate levels of coverage or reimbursement for our Inspire system, or any future products we may seek to commercialize, our commercial success may be severely hindered
5. 05We currently compete and will in the future continue to compete against other companies, some of which have longer operating histories, more established products or greater resources than we do, which may prevent us from achieving increased market penetration and improved operating results
6. 06We are involved, and may become involved in the future, in disputes and other legal or regulatory proceedings that, if adversely decided or settled, could materially and adversely affect our business, financial condition, and results of operations
7. 07without merit, may also result in settlements, injunctions or damages that could have a material adverse effect on our business, financial condition and results of operations
8. 08Our long-term growth depends on our ability to enhance our Inspire system, expand our indications, and develop and commercialize additional products
9. 09Our financial results may fluctuate significantly and may not fully reflect the underlying performance of our business
10. 10Our results of operations could be materially harmed if we are unable to accurately forecast customer demand for our Inspire system and manage our inventory
11. 11We rely on a limited number of third-party suppliers and contract manufacturers for the manufacture and assembly of our products, and a loss or degradation in performance of these suppliers and contract manufacturers could have a material adverse effect on our business, financial condition, and results of operations
12. 12we may lose sales, experience manufacturing or other delays, incur increased costs or otherwise experience impairment to our customer relationships. We cannot guarantee that we will be able to establish alternative relationships on similar terms, without delay or at all
13. 13Performance issues, service interruptions or price increases by our shipping carriers could adversely affect our business and harm our reputation and ability to provide our services on a timely basis
14. 14Consolidation in the healthcare industry or group purchasing organizations could lead to demands for price concessions, which may affect our ability to sell our products at prices necessary to support our current business strategies
15. 15If we are unable to expand, manage and maintain our direct sales and marketing organization we may not be able to generate revenue growth
16. 16To successfully market and sell our Inspire system in markets outside of the U.S., we must address many international business risks
17. 17We primarily rely on our own direct sales force for our Inspire system, which may result in higher fixed costs than our competitors and may slow our ability to reduce costs in the face of a sudden decline in demand for our products
18. 18We face the risk of product liability claims that could be expensive, divert management’s attention and harm our reputation and business. We may not be able to maintain adequate product liability insurance
19. 19when considering the use of our products, either of which could have a material adverse effect on our business, financial condition and results of operations
20. 20If the quality of our Inspire system does not meet the expectations of physicians or patients, then our brand and reputation or our business could be adversely affected
21. 21If we choose to acquire new and complementary businesses, products or technologies, we may be unable to complete these acquisitions or to successfully integrate them in a cost-effective and non-disruptive manner
22. 22Unfavorable global economic conditions could adversely affect our business, financial condition or results of operations
23. 23Failure of a key information technology system, process or site, cyberattacks, or other deficiencies in our cybersecurity could have an adverse effect on our business and operations
24. 24If our facilities are damaged or become inoperable, we may be unable to continue to research, develop, and supply our Inspire system and, as a result, there could be an adverse effect on our business until we are able to secure a new facility and rebuild our inventory
25. 25We rely on third-party distributors to effectively distribute our products in certain markets
26. 26We bear the risk of warranty claims on our Inspire system
27. 27We may need substantial additional funding beyond our existing cash resources and may be unable to raise capital when needed, which could force us to delay or reduce our commercialization efforts or product development programs
28. 28Our ability to use our net operating losses and research and development credit carryforwards to offset future taxable income may be subject to certain limitations
29. 29If we were deemed to be an investment company under the Investment Company Act of 1940, as amended (the “1940 Act”), applicable restrictions could make it impractical for us to continue our business as contemplated and could have a material adverse effect on our business, financial condition and results of operations
30. 30The increasing and evolving focus on sustainability and environmental, social, and governance initiatives from regulators and stakeholders could increase our costs, expose us to new risks, harm our reputation and adversely impact our financial results
31. 31Climate-related events and other events could harm our business

Risks Related to Government Regulation

1. 32Our products and operations are subject to extensive and changing laws, government regulation and oversight both in the U.S. and abroad, and our failure to comply with applicable requirements could harm our business
2. 33We may not receive the necessary approvals or certifications for our future products or expanded indications, and failure to timely obtain necessary approvals or certifications for our future products or expanded indications would adversely affect our ability to grow our business and our results of operations
3. 34The timing of FDA approval of a next generation product could have a significant impact on the carrying value of the inventory of our previous generation product, and therefore our results of operations
4. 35Modifications to our products may require us to obtain new PMAs or approvals of a PMA supplement or certification, and if we market modified products without obtaining necessary approvals or certifications, we may be required to cease marketing or recall the modified products until required approvals are obtained
5. 36Failure to comply with post-marketing regulatory requirements could subject us to enforcement actions, including substantial penalties, and might require us to recall or withdraw a product from the market
6. 37Our products must be manufactured in accordance with foreign, federal and state regulations, and we or any of our suppliers or third-party manufacturers could be forced to recall our installed systems or terminate production if we fail to comply with these regulations
7. 38Any of these actions could significantly and negatively affect supply of our products. If any of these events occur, our reputation could be harmed, we could be exposed to product liability claims and we could lose customers and experience reduced sales and increased costs
8. 39authority or certified by a notified body, may not effectively treat such conditions, which could harm our reputation in the marketplace among physicians and patients
9. 40devices, we may face additional regulatory enforcement action, including FDA or foreign regulatory authority warning letters, product seizure, injunctions, administrative penalties or civil or criminal fines
10. 41If we do not obtain and maintain international regulatory registrations, approvals or certifications for our products, we will be unable to market and sell our products outside of the U.S
11. 42The FDA may modify its enforcement policies with respect to medical software products, and our software products may become subject to extensive regulatory requirements, which may increase the cost of conducting, or otherwise harm, our business
12. 43Legislative or regulatory reforms in the U.S. or the EU may make it more difficult and costly for us to obtain regulatory clearances, approvals or certification for our products or to manufacture, market or distribute our products after clearance, approval or certification is obtained
13. 44are subject to or affected by new and/or existing privacy and data protection laws, any liability from failure to comply with the requirements of these laws could adversely affect our financial condition
14. 45Healthcare policy changes, including recently enacted legislation reforming the U.S. healthcare system, could harm our business, financial condition and results of operations
15. 46Our business involves the use of hazardous materials and our third-party manufacturers must comply with environmental laws and regulations, which may be expensive and restrict how we do business

Risks Related to Intellectual Property Matters

1. 47If we are unable to adequately protect our intellectual property rights, or if we are accused of infringing on the intellectual property rights of others, our competitive position could be harmed or we could be required to incur significant expenses to enforce or defend our rights
2. 48Litigation or other proceedings or third-party claims of intellectual property infringement could require us to spend significant time and money and could prevent us from selling our products or affect our stock price
3. 49If we are unable to protect the confidentiality of our trade secrets, our business and competitive position could be harmed
4. 50We may be unable to enforce our intellectual property rights throughout the world
5. 51Third parties may assert ownership or commercial rights to inventions we develop
6. 52Third parties may assert that our employees or consultants have wrongfully used or disclosed confidential information or misappropriated trade secrets
7. 53Changes in U.S. and foreign patent laws may limit our ability to obtain, defend and/or enforce our patents

Risks Related to Our Common Stock

1. 54The market price of our common stock may be volatile and fluctuate substantially, which could result in substantial losses for purchasers of our common stock
2. 55Provisions in our governing documents and under Delaware law could make an acquisition of us more difficult and may prevent attempts by our stockholders to replace or remove our current management
3. 56Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable future, capital appreciation, if any, will be your sole source of gain
4. 57Changes in U.S. and foreign tax laws could have a material adverse effect on our business, cash flow, results of operations and financial condition
5. 58Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud
6. 59Securities analysts may not publish favorable research or reports about our business or may publish no information at all, which could cause our stock price or trading volume to decline